As societal attitudes and legislative landscapes regarding cannabis evolve, the potential for federal legalization looms. This shift, particularly if the drug’s scheduling moves from Schedule I to Schedule III, could greatly benefit multi-state operators in the cannabis sector.
With medical cannabis legalized in 38 states currently, the market is expected to grow significantly in the upcoming years. BDSA, a leading cannabis industry market intelligence platform, anticipates U.S. cannabis sales to skyrocket to $32.4 billion this year and reach $46 billion by 2028, driven notably by the adult-use segment.
Amid the U.S. Drug Enforcement Administration’s (DEA) reevaluation of its cannabis classification in 2024, there has been an uptick in interest in cannabis stocks. The increased curiosity, coupled with the growth potential, has proved beneficial for companies like Cresco Labs Inc. (CRLBF) and Tilray Brands, Inc. (TLRY), both of which…
